Russia's R-Pharm to invest $237 million in further development

13 October 2015

R-Pharm, one of Russia’s largest pharmaceutical producers, has signed an agreement with Vnesheconombank (VEB), on the provision of a loan in the amount of 14.6 billion roubles (~$237 million), which should help the company to implement its ambitious investment projects during the next several years.

It is planned that the borrowed funds will be used for the construction of a plant for the production of pharmaceutical substances in the city of Rostov and a second stage of the plant for the production of finished dosage forms in Yaroslavl. In addition, part of the loan will be invested in the completion of R&D activities for seven original drugs, which are currently designed by R-Pharm.

The terms of the loan are not disclosed. Representatives of R-Pharm declined to comment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK